公开(公告)号：EP1718615A1

公开(公告)日：2006-11-08

申请号：EP05704807.6

申请日：2005-02-07

申请人： AstraZeneca AB

发明人： DAVID, Laurent ,  GUSTAFSSON, Jörgen ,  LAWITZ, Karolina ,  MUSSIE, Tesfaledet ,  NIKITIDIS, Antonios

IPC分类号： C07D215/54 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  A61K31/47 ,  A61P37/00 ,  A61P11/06

CPC分类号： C07D409/12 ,  C07D215/54 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

摘要： The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is -CHOH or -C=O;

公开(公告)号：EP1625127A1

公开(公告)日：2006-02-15

申请号：EP04731527.0

申请日：2004-05-06

申请人： AstraZeneca AB

发明人： DAVID, Laurent ,  HANSEN, Peter

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P11/06 ,  A61P37/00 ,  A61P19/02 ,  A61P29/00

CPC分类号： C07D471/04

摘要： The present invention relates to novel azaindole compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them.

公开(公告)号：EP1625127B1

公开(公告)日：2007-05-23

申请号：EP04731527.0

申请日：2004-05-06

申请人： AstraZeneca AB

发明人： DAVID, Laurent ,  HANSEN, Peter

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61P11/06 ,  A61P37/00 ,  A61P19/02 ,  A61P29/00

CPC分类号： C07D471/04

摘要： The present invention relates to novel azaindole compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them.

公开(公告)号：EP2016068A1

公开(公告)日：2009-01-21

申请号：EP07732652.8

申请日：2007-05-02

申请人： AstraZeneca AB

发明人： DAVID, Laurent ,  FOOTE, Kevin Michael ,  LISIUS, Annea

IPC分类号： C07D401/04 ,  A61K31/44 ,  A61P35/00 ,  C07D417/14

CPC分类号： C07D401/04 ,  C07D417/14

摘要： The invention concerns pyrazole derivatives of Formula( I) or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.